The global Gut Microbiota-Derived Therapeutics market was valued at USD 1.48 billion in 2025 and is projected to reach USD 6.23 billion by 2033, growing at a CAGR of 19.70% from 2026 to 2033. The Global Gut Microbiota-Derived Therapeutics Market is experiencing consistent growth driven by rising prevalence of gastrointestinal, metabolic, and immune-related disorders, increasing scientific understanding of the gut–brain axis, and rapid advancements in microbiome research and biotherapeutic development
2 Views